Los Angeles, CA
Joined December 2012
- Tweets12.1K
- Following178
- Followers12.7K
- Likes27.3K
Gregg Fonarow MD retweeted
How do life stages shape women's heart health? A landmark series of American Heart Association publications explores connections among hormonal changes, mental health and well-being and cardiovascular health. Sadiya S. Khan, M.D., M.Sc., FAHA, chair of the collaborative writing group, talks about the whole life view of women's heart health. newsroom.heart.org/file/dr-k…
Gregg Fonarow MD retweeted
LBB Area Pacing vs RV Pacing for AV Block and Preserved Left Ventricular Function:
The #LEAP-Block Trial
📍499 patients with #LVEF ≥50% randomized to LBBAP vs #RVP across 14 Chinese hospitals.
📍 Primary endpoint: 2.4% vs 12.5% favoring #LBBAP (P=0.003).
📍 HF events: 3.4% vs 11.3% with LBBAP vs RVP.
📍 LBBAP ⬇️ the 24-month primary endpoint risk (HR 0.37, 95% CI 0.19–0.73), with no significant differences in mortality or device complications.
#LEAPBlock #Cardiology #HeartFailure #Pacing
jamanetwork.com/journals/jam…
@JAMACardio #JAMA
Gregg Fonarow MD retweeted
What actually drives quality of life(QoL) in #HFrEF?Analysis of 2 HFrEF registries finds low KCCQ-QoL score is driven by symptoms &social limitations(effect size 0.48-0.60)less by physical limitations alone(effect size=0.34) Findings held across age & sex
ahajournals.org/doi/10.1161/…
🫀 Full quadruple GDMT for US HFrEF:
💊 4 generic pills, ~$25/month ➡️
❤️ ~114K lives saved/year
🏥 ~864K hospitalizations avoided
💰 $16.3Billion net savings
⚠️ Only 18% get all 4
💻 One of the best opportunities in healthcare for AI to improve care, outcomes & cost?
Gregg Fonarow MD retweeted
Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure
Guideline-directed medical therapy is often underutilized in patients with HF.
Consider simultaneous or rapid sequence initiation of a combination therapy for patients with HF with mildly reduced or preserved ejection fraction
@mvaduganathan @gcfmd @CMichaelGibson @SJGreene_md @DrMarthaGulati @HFA_President @GianluSava
jacc.org/doi/10.1016/j.jacad…
Gregg Fonarow MD retweeted
MRAs are effective for #CHF across the entire LVEF spectrum. Guidelines, label indications, & patient comorbidities must be considered when selecting an MRA for GDMT combination therapy regimens. Read the state-of-the-art review in #JACCAdvances!
@GCFMD
bit.ly/4ss6kCi
Gregg Fonarow MD retweeted
💰 The broader annual cost burden of Heart Failure (HF) is projected to reach $858 billion by 2050. Yet, we hold an extraordinarily cost-effective solution in our hands today. See below for more + click here for more insights from our HF STATS 2026 report bit.ly/3ULm2vS
💊Is evolocumab cost-effective before a first MI or stroke?
📊 VESALIUS-CV lifetime model at $3,107/yr
❤️ −0.24 MACE/person
✅ ICER $71,162/QALY; scenarios $20K–$51K
🎯 All below the $120K AHA/ACC threshold
⚠️ Preprint
🔗 doi.org/10.64898/2026.07.23.…
💊 PCSK9 inhibitors in the US, Oct 2026:
💉 Repatha: ~60%↓LDL | CVOT ✅ | $239/mo
💉 Praluent: ~45–60% | CVOT ✅ | $225/mo
🩺 Leqvio: ~50% | CVOT ⏳ | no DTC
💉 Lerochol: ~56–60% | CVOT ❌ | $199/mo
💊 Lipfendra (oral!): ~56–59% | CVOT ⏳ | $315 list
#Lipids
Trial after trial, vitamin D supplements keep coming up empty:
💊 VITAL (25,871): no CV benefit
🧬 83,000 across 21 RCTs: null
💀 80 RCTs: no CV benefit
🩺 SIMPLIFIED (2026, dialysis): no ☠️ benefit, HR 0.94
Billions spent on RCTs
Still nothing
Low D is a marker
Gregg Fonarow MD retweeted
👏 Congratulations go out to Amrut Ambardekar, MD, FHFSA of the University of Colorado Health for being named this year's Distinguished HFSA Service Award winner at #HFSA2026
Learn more 👉 youtube.com/watch?v=T_AGfOX4…
Gregg Fonarow MD retweeted
CMS's 2027 HF model has no measure for MRAs or SGLT2i, and doesn't require ARNI.
Modeled: every eligible U.S. HFrEF patient on all 3 at generic prices (~$227/yr) could prevent ~87.5K deaths and save ~$14.1B net per year.
Keykhaei et al, JACC HF 2026
#HFrEF #Cardiology
💊 Does stopping cardiovascular meds make patients feel better?
🔬 6 deprescribing RCTs, 3,748 older/frail patients
😐 QoL better in just 1 of 5
⚠️ Adverse events reduced: 0 of 6
⚖️ Death/hospitalization better: 0 of 6
🚫 Rarely helpful 😳
#Deprescribing
Gregg Fonarow MD retweeted
🫀 Quadruple guideline-directed medical therapy (GDMT) offers a profound mortality benefit, yet it remains severely underutilized across Heart Failure (HF) care today. Data from HF STATS 2026 reveals only 18% of patients with HFrEF receive all 4 foundational medication pillars.
Gregg Fonarow MD retweeted
🌟🏅Congratulations to the winner of this year's HFSA Distinguished Mentor Award, Lynne Stevenson, MD of Vanderbilt University Health, for her leadership and mentorship in the #HeartFailure field! #HFSA2026
Stay tuned for more award announcements!
Learn more about Lynne Stevenson, MD here 👉 youtube.com/watch?v=sUci1Cgi…
❓for @CMSGov
Why does the 2027 HF ASM measure beta-blockers and RASi 💊 but not ARNI, MRA or SGLT2i?
Those 3 could prevent:
~88K deaths 💔 a year
~746K 🏥 a year
Saving $14.1B 💰, at $227/yr per patient
What are we missing? 🤷
@ACCinTouch @American_Heart @HFSA @AAHFN
Gregg Fonarow MD retweeted
Heart failure care has advanced, but the US burden continues to grow. A new report shows mortality is rising as more Americans are being affected, with obesity, diabetes, and other comorbidities potentially contributing to the trend. #HeartFailure #PublicHealth bit.ly/4rZGy8a
🫀 Ready to make a difference in #HCM care?
The @American_Heart Hypertrophic Cardiomyopathy Registry is enrolling!
📊 National HCM registry
🏆 Hospital QI recognition
📜 Hospital & pro certification
🩺 Patient support
🤖 AI detection pilot
👉 heart.org/hcmregistry
🚑 ICH patients reach the ED faster than those with ischemic stroke (median 127 vs 175 min from last known well)
🧠 But once stroke severity is accounted for, they're LESS likely to meet ED care targets
⏱️ Time is brain for ICH too
📄 Royan et al, doi.org/10.1001/jamanetworko…
